Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CorMedix (CRMD) Non Operating Income (2016 - 2025)

Historic Non Operating Income for CorMedix (CRMD) over the last 12 years, with Q3 2025 value amounting to $1.2 million.

  • CorMedix's Non Operating Income rose 14097.05% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.1 million, marking a year-over-year decrease of 443.02%. This contributed to the annual value of $3.0 million for FY2024, which is 1577.35% up from last year.
  • Per CorMedix's latest filing, its Non Operating Income stood at $1.2 million for Q3 2025, which was up 14097.05% from $805983.0 recorded in Q2 2025.
  • Over the past 5 years, CorMedix's Non Operating Income peaked at $1.2 million during Q3 2025, and registered a low of -$11066.0 during Q4 2021.
  • Moreover, its 5-year median value for Non Operating Income was $480238.5 (2023), whereas its average is $422448.8.
  • Its Non Operating Income has fluctuated over the past 5 years, first plummeted by 37987.86% in 2021, then skyrocketed by 2464735.41% in 2023.
  • Over the past 5 years, CorMedix's Non Operating Income (Quarter) stood at -$11066.0 in 2021, then surged by 1729.11% to $180277.0 in 2022, then skyrocketed by 301.01% to $722929.0 in 2023, then decreased by 26.91% to $528396.0 in 2024, then surged by 132.82% to $1.2 million in 2025.
  • Its Non Operating Income stands at $1.2 million for Q3 2025, versus $805983.0 for Q2 2025 and $518618.0 for Q1 2025.